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Abstract 
Aims: Lack of adherence to smoking cessation medication regimens is assumed to play a 
significant role in limiting their effectiveness. This study aimed to assess evidence for this 
assumption. 
Methods: A systematic search was conducted, supplemented by expert consultation, of arti-
cles reporting on randomised trials and observational studies examining the association be-
tween adherence to cessation medication and the success of quit attempts. To rule out re-
verse causality, only studies where adherence was assessed prior to relapse were included. 
Five studies met the inclusion criteria and results were extracted independently by two re-
searchers. Heterogeneity between studies precluded a pooled analysis of the data. 
Results: Studies varied widely with regard to both the definition of adherence and outcome 
measures. Included studies only addressed adherence to nicotine replacement therapy. One 
study of lozenge use found that amount of medication used between 1 and 2 weeks after the 
quit date predicted abstinence at 6 weeks (adjusted OR for ‘high’ versus ‘low’ lozenge use 
1.25; 95% confidence interval (CI) = 1.05-1.50; p<0.02). Similarly, one study found a signifi-
cant impact of oral nicotine consumption during the first week on abstinence at four weeks 
(adjusted OR per additional mg/d: 1.05%; CI = 1.01-1.10). Another study found that partici-
pants using nicotine replacement therapy for at least five weeks were significantly more likely 
to self-report continuous abstinence at 6 months. The remaining two studies failed to find a 
significant effect of treatment duration on outcome at one and two years but had very low 
power to detect such an effect. 
Conclusions: There is modest evidence to support the assumption that lack of adherence to 
nicotine replacement therapy regimens undermines effectiveness in clinical studies.  
 
 
Key words: adherence, cessation, compliance, medication, smoking, success, quitting, nico-
tine replacement therapy, bupropion, varenicline 
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Introduction 
Data from numerous randomised controlled trials clearly demonstrate the effectiveness of 
nicotine replacement therapy (NRT) (1), bupropion (2) and varenicline (3) in promoting long-
term abstinence from smoking. However, some population studies suggest that pharma-
cotherapy may be considerably less effective outside clinical trials (4). One possible explana-
tion for the finding of lower effectiveness in the ‘real world’ is that many smokers fail to ad-
here to treatment recommendations, i.e. they tend to take inadequate doses (5, 6) or discon-
tinue treatment early (7). The amount of medication taken is likely to have a moderating ef-
fect on the effectiveness of drugs used to assist quit attempts. In randomised controlled tri-
als, great care is being taken to ensure good patient adherence. Nevertheless, a substantial 
proportion of study participants do not appear to follow dosing instructions: In one early trial 
on nicotine gum in which patients were advised to use their medication for at least three 
months, 43% of participants in the active treatment arm stopped taking the gum within 4 
weeks (8). Similarly high rates of early discontinuation have been reported for the nicotine 
patch (9), bupropion (10) and varenicline (11). There is evidence to suggest that adherence 
to cessation medication is even lower outside clinical trials: In one retrospective survey from 
the United States, past NRT users who had bought their medication over the counter report-
ed a median treatment duration of 9.8 days (12) which is in contrast with manufacturer rec-
ommendations (at least 8 weeks). In one prospective study from China, 84% of participants 
used NRT for less than 4 weeks, and 44% used it for less than 7 days (13). 
There is currently no consensus on what defines adequate adherence in the context of 
smoking cessation medication. Adherence can be defined as compliance with recommenda-
tions on treatment duration or as compliance with a given dosing regimen. A general defini-
tion of good adherence to oral medication for the treatment of chronic diseases is use for at 
least 80% of the recommended duration (14). Due to the diversity regarding the route of ad-
ministration of medications to support smoking cessation (i.e., nasal, dermal or oral applica-
tion), a universal criterion for adherence to these drugs is particularly hard to define. As a 
consequence, studies addressing adherence have used a wide range of definitions, e.g. ‘tak-
ing at least 1 dose of medication for at least 80% of the treatment days’ (15), ‘chewing at 
least 10 pieces of nicotine gum per day’ (16), and compliance indices calculated as the pro-
portion of scheduled doses that had actually been taken (17, 18).  
Some of the reasons for early termination of cessation medication quoted most frequently in 
surveys include adverse events (12, 15, 19-21), medication cost (12, 21) and no perceived 
need to take medication to stop smoking (12, 19, 20). The most important precipitating factor 
for medication non-adherence, however, is likely to be relapse to smoking. In a recent inter-
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net survey on the use of various medications to support a quit attempt (21), 42% of partici-
pants stated they had stopped using the nicotine patch because they had relapsed to smok-
ing; the corresponding proportions for other medications were 52% (nicotine gum), 46% (nic-
otine lozenge/tablet), 54% (nicotine inhaler), 26% (bupropion), and 18% (varenicline). Stud-
ies assessing the association between adherence to medication and success of a quit at-
tempt might not yield valid results if non-adherence was not the cause but the consequence 
of relapse in a substantial proportion of cases. This effect which has also been termed ‘re-
verse causality’ (22) is likely to lead to an overestimation of the effect of treatment duration 
on quitting success as more treatment failures with short durations of treatment would be 
included in the analysis. This review aims to summarise the available evidence on the asso-
ciation between adherence and abstinence in studies controlling for potential bias due to 
relapse precipitating discontinuation of medication use. 
 
Methods 
Search strategy 
Online databases (PubMed, WebOfScience, and the Cochrane Tobacco Addiction Group 
specialized register) were searched up to 28 February 2013 with the terms: ‘smoking cessa-
tion AND (adherence OR compliance) AND (abstinence OR success)’. An additional search 
included the terms: ‘(nicotine replacement OR bupropion OR varenicline) AND (adherence 
OR compliance)’. Search terms were inclusive in an attempt to locate all studies examining 
the association between adherence and abstinence. A hand-search of the reference lists of 
included studies was also carried out, and leading researchers in the field were contacted. 
Studies identified by these searches were screened for eligibility by two reviewers (T.R. and 
A.H.), with 98.8% agreement. In six cases, consensus was reached by involving a third re-
viewer (J.B.) who was blinded to the other reviewers’ assessments. Details of the method of 
data collection, outcome measures, recall period, participant characteristics, sample size, 
response rate and analysis method were extracted and compiled into a table independently 
by two researchers (T.R. and A.H). All discrepancies were checked against the study papers, 
discussed and resolved.  
Inclusion and exclusion criteria 
We included primary and secondary analyses of prospective randomised controlled trials and 
observational studies which specifically addressed the association between medication ad-
herence and abstinence in adult smokers. Due to potential confounding by recall bias, purely 
retrospective surveys were not included. With regard to pharmacotherapies, only studies 
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involving the use of nicotine replacement therapy, buproprion or varenicline (used alone or in 
combination) were included as these are considered first-line treatments in most countries 
(23, 24). We only included original articles written in English and published in peer-reviewed 
journals. Review articles, personal communications to editors, commentaries, study proto-
cols, case studies, studies on smoking reduction and studies involving pregnant women or 
adolescents were excluded. 
As outlined above, an important potential confounder in studies assessing the association 
between treatment adherence and abstinence is relapse leading to non-adherence in which 
case non-adherence is not the cause but the consequence of relapse. There are two ways to 
control for this bias: 
a) establishing the chronological sequence of non-adherence and relapse during a study 
b) assessing adherence during a pre-specified treatment period and determine abstinence 
only in those who had been continuously abstinent throughout this period 
Only studies reporting a valid strategy to control for reverse causality were included in this 
review. 
Outcome measures 
There was no uniform definition of adherence; most studies used retrospective self-reports of 
drug use to assess adherence while some interviewed participants daily via an interactive 
voice response system or established adherence using medication dispensers with an elec-
tronic counting device fitted to the bottle cap. Details of the definitions and methods used in 
individual studies are given in Table 1 and Table S1 (online supplement of this article). 
Abstinence was defined as the proportion of participants who achieved point prevalence, 7-
day point prevalence or continuous abstinence up to a given time-point. The assessment of 
abstinence was based on self-report or biochemical validation by exhaled carbon monoxide 
or salivary cotinine concentrations, and different cut-off values were used in different studies.  
Data analysis 
Due to variation between the studies with regard to the definitions of adherence and absti-
nence, results could not be pooled statistically. Consequently, the evidence was synthesized 
in a narrative review. 
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Results  
Search results 
The electronic literature search yielded 498 articles. For 119 of these, eligibility could not be 
determined from the abstract so full text versions were retrieved and studied in detail. Thirty 
further eligible articles were identified through a review of reference lists and one additional 
article through contacting experts in the field. Of the resulting 150 articles, 37 assessed the 
association between adherence and abstinence, but only five reported using a strategy to 
control for potential confounding by reverse causality and were thus included in this review. 
The authors of one additional study (25) took a different approach to controlling for such con-
founding in that they adjusted for smoking status during the first three weeks of a trial in a 
logistic regression of predictors of abstinence at six weeks. In this regard, that study did not 
meet the inclusion criteria for this review; however, its findings were similar to the results of a 
study from the same group that was included in this review (22). 
Description of included studies 
All five articles assessed the association between NRT use and abstinence; this research 
aim was explicitly stated in three studies (22, 26, 27) and addressed in sub-group analyses in 
the other two (28, 29). Two articles presented secondary analyses of randomised controlled 
trials (22, 27), and two articles provided data from prospective observational studies (26, 28). 
The only article reporting original results of a randomised controlled trial referred to a study of 
nicotine gum versus placebo in addition to nicotine patch treatment in a small sample (n = 
96) of alcohol-dependent smokers in an early phase of out-patient alcohol treatment (29).  
One study was conducted in the United Kingdom (27), one in the United States (29), one 
enrolled patients in both countries (22), and the two remaining studies were from Switzerland 
(26) and Germany (28), respectively. Baseline sample sizes ranged from 92 to 1,030, study 
populations were predominantly white, the mean/median age of participants ranged from 40 
to 47 years, 29% to 54% of participants were female, and the mean/median number of ciga-
rettes smoked daily ranged from 20 to 25. The length of follow-up ranged from four weeks to 
two years. Each study took a different approach to measuring adherence (see below). Smok-
ing outcome was assessed as continuous abstinence and validated by exhaled carbon mon-
oxide (CO) in four of the five studies (22, 26, 27, 29). The association between adherence 
and abstinence was assessed by means of a logistic regression in four and by a χ2 test in 
one study (28). 
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Details of the 37 articles addressing the association between adherence and abstinence but 
not controlling for relapse as a cause for non-adherence are provided in Table S1 in the 
online supplement to this article. Information on included studies is summarised in Table 1.  
Summary of the evidence 
Due to the heterogeneity of the studies discussed above, this section provides short narrative 
summaries of the five included studies. 
1. Shiffman (22) conducted a secondary analysis of a randomised controlled trial of nicotine 
lozenges versus placebo in 1,030 smokers. Participants were instructed to use lozenges 
for 6 weeks. Adherence to study medication was monitored daily during the first two 
weeks of the trial, using an interactive voice response system. In the absence of an a pri-
ori definition of adherence, study participants were categorised as ‘high’ lozenge users or 
‘low’ lozenge users based on a median split of the entire cohort. The mean number of 
lozenges used per day was 10.2 ± 2.5 in the ‘high’ users group and 5.1 ± 1.9 in the ‘low’ 
users group. Smoking outcome was defined as continuous 28-day abstinence, validated 
by exhaled CO at 6 weeks. In order to control for confounding by non-adherence due to 
relapse, the analysis (logistic regression) only included participants that had remained 
abstinent for the first two weeks of the trial (i.e. the period during which adherence was 
monitored daily). Thus, a dichotomised parameter of lozenge use during the first two 
weeks was examined as a predictor of continuous abstinence at six weeks in those who 
had been randomised to active treatment and who had not relapsed during the first two 
weeks (sample size not reported). The odds of continuous abstinence were significantly 
higher for ‘high’ lozenge users in both the unadjusted model (OR 1.60; 95% confidence 
interval (CI): 1.13-2.27; p<0.009) and a model adjusting for gender and numbers of ciga-
rettes smoked at study entry (OR 1.25; CI = 1.05-1.50; p<0.02). When entered as a con-
tinuous variable, each additional lozenge per day significantly increased the odds of 
achieving abstinence by 10% (4-16%) in both the unadjusted and the adjusted model. 
2. Hollands et al. (27) report the results of a secondary analysis of data from a randomised 
controlled trial in a primary care setting. All participants received a nicotine patch (dose 
tailored to the number of cigarettes smoked per day) and additional oral NRT. Partici-
pants were randomised to have their oral dose calculated based on (a) their genotype 
(presence/absence of a specific mutation; see (30) for details) or (b) their level of nicotine 
dependence as measured by the Fagerström Test of Nicotine Dependence (FTND (31)). 
Adherence during the first trial week was operationalised as NRT consumption and 
measured in mg/d. Smoking outcome was defined as 4-week abstinence, validated by 
exhaled CO. In order to control for confounding by non-adherence due to relapse, the 
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analysis (logistic regression) only included participants that had remained abstinent for 
the first trial week. Thus, a continuous measure of NRT use during the first week was ex-
amined as a predictor of continuous abstinence at four weeks in those who had not re-
lapsed during the first week (n = 285). The odds of abstinence increased by 5% (CI = 1-
10%) per additional mg/d in a model adjusting for various confounders, including nicotine 
dependence and treatment arm of the randomised trial. 
3. Cooney et al. (29) randomised 96 alcohol-dependent smokers in an early phase of out-
patient alcohol treatment (two study sites) to nicotine gum versus placebo on top of a 12-
week course of nicotine patches. Participants were encouraged to use between 6 and 20 
pieces of gum per day. There was no a priori definition of adherence; medication use was 
assessed two weeks after the target quit date by eliciting a 7-day retrospective report of 
gum use during patient interviews. The frequency of gum use at two weeks was entered 
into logistic regressions of predictors of continuous abstinence (validated by exhaled CO) 
at 3, 6 and 12 months. In order to control for confounding by non-adherence due to re-
lapse, the final analysis only included participants that had remained abstinent during the 
first two weeks (n = 37). After adjusting for educational level, depression score, nicotine 
dependence and study site, more frequent use of study medication (gum or placebo) dur-
ing the second week of the first two treatment weeks increased the odds of continuous 
abstinence at 3, 6 and 12 months by 4% (CI = 1% to 6%; p = 0.008), 4% (1% to 8%; p = 
0.045) and 3% (-3% to 10%; p = 0.364), respectively. 
4. Raupach et al. (28) followed up 369 participants of a hospital-based smoking cessation 
programme for 6 months who had been encouraged to purchase NRT themselves. Par-
ticipants provided self-reports of continuous abstinence and treatment duration at the six-
month telephone follow-up. In the absence of an a priori definition of adherence, this 
study considered a minimum treatment duration of five weeks to indicate good adher-
ence. In order to control for confounding by non-adherence due to relapse, analysis of 
the association between adherence and abstinence was restricted to those who had ei-
ther remained abstinent or relapsed only after discontinuing medication use (n = 127). 
Within this sub-group, self-reported continuous abstinence rate at 6 months was signifi-
cantly higher if medication had been used for at least five weeks (61.0% vs. 42.6%; p = 
0.039). 
5. Schneider et al. (26) followed up 92 smokers who were provided with nicotine nasal 
spray to be used ad libitum for up to 18 months. During the first month of the study, spray 
use was monitored using a metered-dose inhaler fitted with an electronic device record-
ing the date and time of each use. There was no a priori definition of adherence, and con-
tinuous abstinence from the end of the first month was assessed and validated by ex-
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haled CO at a clinic visit two years after study entry. The methods report that in order to 
control for confounding by non-adherence due to relapse, only participants who had re-
mained abstinent during the first month (n = 48) were included in the final analysis. In the 
multiple regression, median daily consumption of nasal spray was not predictive of con-
tinuous abstinence at 2 years (no ORs provided). It should be noted that the reporting in 
the results was brief and without exact figures, which meant there was no numerical con-
firmation of the stated methods that the analysis would be limited to the appropriate sub-
group. 
 
Discussion 
Main findings of this review 
The results of this review indicate that there is a substantial lack of high-quality studies as-
sessing the association between treatment adherence and subsequent quitting success. The 
two studies with the most rigorous control for confounding by reverse causality (22, 27) both 
found a significant effect of the amount of medication taken and quit rates at four to six 
weeks. The only other study reporting a significant effect on continuous 6-month abstinence 
(28) was limited by its observational design, a lack of biochemical validation of smoking sta-
tus and potential confounding by participant motivation and recall bias. The two remaining 
studies which did not find significant effects after one (29) and two (26) years appeared un-
derpowered as sample sizes were small. Since all five studies that met our inclusion criteria 
addressed adherence to NRT products, no conclusions can currently be drawn on the asso-
ciation between adherence and treatment success for other first-line treatments such as bu-
propion and varenicline, or combinations of treatments. 
Strengths and limitations 
In order to ensure the inclusion of all relevant articles, two independent reviewers assessed 
all publications identified by an extensive search of the literature. Agreement between re-
viewers was high, and all discrepancies were resolved by involving a third independent re-
viewer. We used conservative inclusion criteria in order to restrict this review to studies with 
relatively rigid methodology. This led to the exclusion of one study (25) that did not control for 
reverse causality in the way set out in our criteria but produced similar results as a compara-
ble study with a larger sample size.  
Only original articles written in English were included in this review. A total of 25 Pubmed 
citations were excluded due to their being written in Spanish (n = 9), German (n = 8), Polish 
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(n = 3), French (n = 2), Dutch (n = 1), Turkish (n = 1), or Japanese (n = 1). Six of these were 
review articles and had to be excluded for that reason, and one was a commentary. The ab-
stracts of the remaining 18 articles were screened, and none of these assessed abstinence 
in relation to medication adherence. Thus, exclusion of articles not written in English is un-
likely to have confounded our results. 
Another limitation of this review is that we were unable to conduct quantitative quality as-
sessments of the included studies. This was due to the fact that there are currently no uni-
versally accepted quality criteria for the type of studies included in this review; available tools 
to assess the quality of such studies have been criticised for their low reliability (32, 33). In-
stead, we used our field-specific expertise to provide qualitative judgments on the quality of 
included studies. Only two of the five included studies reported results from randomised-
controlled trials; however, these were derived from secondary analyses. Thus, the associa-
tion between adherence and abstinence was not a primary endpoint of these studies. The 
remaining three studies enrolled specific patient groups (i.e., alcohol-dependent smokers or 
smokers highly motivated to quit who reported to a university-based cessation clinic) which 
limits the generalisability of their findings to a general smoker population. Sample size was 
below 100 in two studies, and drop-out rates approached 50% in one study. Finally, four of 
the five studies did not use an a priori definition of adherence. In summary, the quality of in-
cluded studies was low to moderate, and more well-designed studies are clearly needed.  
Interpretation of the available evidence is further hampered by the lack of a universal defini-
tion of adherence and a consensus on how to control for reverse causality. Recently, it has 
been suggested to report adherence as the percentage of prescribed amount or to directly 
calculate medication intake (27). Excluding participants who stopped using NRT because 
they abandoned their quit attempt (28) would be desirable but can only be done if all relevant 
data are available. The alternative approach taken by some authors (i.e. relating adherence 
during a short interval at the beginning of a trial to abstinence at a later stage) is more prob-
lematic as it does not account for (non-)adherence between the initial adherence period and 
the time when the quit attempt ended. While one study on medium-term abstinence retro-
spectively assessed adherence throughout the entire treatment phase (28), the two other 
small studies assessing abstinence at one (29) or two years (26) only controlled for reverse 
causality during the first 2-4 weeks of the treatment phase. Thus, even in these studies, a 
residual bias arising from reverse causality cannot be excluded. 
Suggestions for future research 
The definitions of adherence used in these studies were not primarily based on theoretical 
considerations including the mode of action of pharmacotherapies but mainly derived post 
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hoc from the data (e.g., median split of the number of lozenges taken per day or an arbitrary 
cut-off of at least 5 weeks of treatment). The fact that relapse tends to occur early during a 
quit attempt (34) suggests that the first weeks of treatment are most important, but no firm 
conclusions can be drawn from the available literature. Identification of a minimum treatment 
duration (or amount of medication taken per day) for pharmacotherapy to be effective is im-
portant in order to design interventions that may increase adherence (35-38). Ideally, such 
interventions would be informed by an analysis of modifiable predictors of adherence.  
Despite the lack of a universal (and clinically meaningful) definition of good adherence, a 
number of studies have reported on predictors of adherence. These studies used various 
designs including secondary analyses of randomised controlled trial data (19), prospective 
observations (13) and retrospective surveys (20, 39). Factors that were found to be associat-
ed with better adherence by most studies included male gender (13), more advanced age 
(13, 15, 19, 20), higher self-efficacy (19, 40), lower smoking rate at study entry (15), and 
more intensive concomitant counselling (41). However, since non-adherence may be precipi-
tated by relapse in up to 50% of cases (21), these might reflect characteristics associated 
with higher odds of successful quit attempts regardless of medication adherence. In fact, 
most of the predictors listed above have been found to independently increase quit rates in a 
number of studies (42).  
In conclusion, we found some evidence in studies of nicotine replacement therapy that low 
rates of adherence may be limiting effectiveness in clinical trials. These findings need to be 
confirmed using more rigorous methods (e.g. by assessing adherence using medication dis-
penser systems with an electronic monitoring device (37) up to a pre-defined follow-up point 
or the end of a quit attempt). They also need to be extended to other stop smoking medica-
tions and to use of stop smoking medicines outside of clinical studies. 
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Tables 
 
ID 
Country, Year 
and Study 
Population 
Participant 
characteristics 
Study design 
Length of 
follow-
up
a
 
Methods of 
recruitment 
Definitions and measurements Sample size Analysis method (incl. con-
trol of confounders) 
Main findings regarding 
the association between 
adherence and abstinence adherence success Baseline Follow-up 
(22) 
Countries: United 
Kingdom & USA 
Year of study: not 
reported 
Population: partici-
pants of a smoking 
cessation trial who 
were abstinent during 
the first two weeks 
mean age: 43.3 ± 
12.1 yrs 
55% women 
94% white 
mean cig/d: 21.0 ± 
10.0  
mean FTND: 4.1 ± 
2.4 
secondary analysis of 
an RCT of nicotine 
lozenges (2 or 4 mg) 
vs. placebo 
6 weeks not reported 
adherence during the 
first 2 weeks was 
monitored daily (IVR 
system) 
definition of adherence: 
‘high lozenge use’ based 
on a median split of all 
participants; group 
means: 10.2 ± 2.5 vs. 
5.1 ± 1.9 lozenges per 
day 
continuous 28-day 
abstinence at 
week 6, validated 
by CO<10 ppm 
1030 of 
which 612 
received 
verum and 
418 placebo 
1020 
logistic regression for predictors of 28-
day abstinence at week 6, adjusted for 
gender and cig/d 
control for relapse: exclusion of 
participants who had smoked during 
the first 2 study weeks 
OR of abstinence for high vs. low 
lozenge use (participants in the 
verum group only): 
- unadjusted: 1.60 (1.13-2.27) 
- adjusted: 1.25 (1.05-1.50) 
OR of abstinence per additional 
lozenge/day: 
- unadjusted: 1.10 (1.04-1.16) 
- adjusted: 1.10 (1.04-1.16) 
significant treatment-by-adherence 
interaction 
(27) 
Country: United 
Kingdom 
Year of study: 2007-
2009 
Population: smokers 
≥10/d 
mean age ∼47 yrs 
∼54% women 
∼90% white 
∼21 cig/d 
mean FTND ∼5.5 
RCT of different ways 
to tailor oral NRT in 
addition to NRT 
patches and counsel-
ling 
4 weeks 
Patients 
attending one 
of 29 primary 
care practices 
in Birmingham 
& Bristol were 
directly 
approached 
Consumption (mg/d) 
during the first week 
was measured by self-
report and pill counts 
and recorded in daily 
diaries 
Adherence = proportion 
of prescribed dose 
Self-reported 4-
week abstinence, 
validated by 
CO<10 ppm 
633 285 
logistic regression for predictors of 4-
week abstinence, adjusted for trial 
arm, genotype, cig/d, FTND, length of 
previous quit attempts 
control for relapse: exclusion of 
participants who had smoked during 
the first study week 
OR of abstinence per additional 
mg/d consumed: 
- unadjusted: 1.03 (0.99-1.07) 
- adjusted: 1.05 (1.01-1.10) 
(29) 
Country: USA 
Year of study: 2004-
2007 
Population: patients 
with a diagnosis of 
alcohol abuse/ depen-
dence and smoking 
≥15/d 
mean age ∼45 yrs 
∼29% women 
∼90% white 
∼25.5 cig/d 
mean FTND ∼6 
RCT of nicotine gum vs. 
placebo in addition to 
a patch and behav-
ioural therapy 
3, 6 and 12 
months 
radio & news-
paper adver-
tisements  
referrals from a 
substance 
abuse clinic 
no a priori definition of 
adherence 
measurement: 7-day 
retrospective report of 
the frequency of gum 
use, assessed 2 wks 
after target quit date 
self-reported 
continuous 
abstinence at all 
time points, 
validated by CO 
<10 ppm 
96 of which 
45 received 
verum  
follow-up data 
based on the 
verum group (n 
= 45): 
3 months: 37 
6 months: 32 
12 months: 30 
logistic regression for continuous 
abstinence at different time-points, 
adjusted for education level, depres-
sion score, FTND and study site; 
control for relapse: Assessment of 
adherence at 2 weeks included only 
those who were still abstinent (n = 37) 
adjusted ORs for continuous 
abstinence at... 
- 3 months: 1.04 (1.01-1.06) 
- 6 months: 1.04 (1.01-1.08) 
- 12 months: 1.03 (0.97-1.10) 
(28) 
Country: Germany 
Year of study: 2003-
2006 
Population: smokers 
(general population 
and hospital staff) 
median age: 45 yrs 
58.8% women 
median cid/g: 20 
median FTND: 5 
prospective observa-
tional study of a 
hospital-based 
smoking cessation 
clinic; participants self-
selected to use NRT 
6 months 
local newspa-
per articles, 
posters and 
flyers 
no a priori definition of 
adherence 
self-reported 
continuous 6-
month abstinence; 
no biochemical 
validation 
369 of which 
182 self-
selected to 
use NRT 
127 partici-
pants used NRT 
and did not 
relapse before 
stopping NRT 
χ
2
 test 
control for relapse: participants who 
relapsed before stopping NRT were 
excluded 
continuous 6-month abstinence 
rates for NRT use >35 days vs. <35 
days: 61.0% vs. 42.6%; p=0.039 
(26) 
Country: Switzerland 
Year of study: 1996-
1997 
Population: smokers 
≥15/d 
median age: 40 yrs 
46.7% women 
median cig/d: 25 
median FTND: 5 
prospective observa-
tional study of 
prolonged use (up to 
18 months) of nicotine 
nasal spray 
24 months 
referrals to the 
smoking 
cessation unit 
and advertise-
ments in a 
hospital  
no a priori definition of 
adherence  
MDIlog: adherence was 
only assessed for the 
first month 
self-reported 
continuous 
abstinence from 
mo 1 to mo 24, 
validated by 
CO<10 ppm 
92 
82 of which 48 
were ‘totally 
abstinent’ after 
1 month 
multiple logistic regression for 
predictors of abstinence 
control for relapse: pts. who smoked 
at 1 mo were excluded 
Median daily consumption of nasal 
spray was not predictive of absti-
nence (no ORs provided). 
 
Table 1: Characteristics of included studies. yrs, years; cig/d, cigarettes per day; FTND, Fagerström Test of Nicotine Dependence; RCT, randomised controlled 
trial; NRT, nicotine replacement therapy; MDILog, metered-dose inhaler chronolog; IVR, interactive voice response; CO, carbon monoxide; ppm, parts per million; 
PP, point prevalence; pts, patients; OR, odds ratio 
a
 Unless otherwise stated, length of follow-up refers to the time point used to establish the association between adherence and abstinence 
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Figures 
 
Figure 1: Flowchart of the study selection and exclusion process 
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Supporting information 
 
Additional Supporting Information may be found in the online version of this article: 
 
Table S1: Characteristics of studies which were excluded due to a lack of control for con-
founding by non-adherence due to relapse. yrs, years; cig/d, cigarettes per day; FTND, 
Fagerström Test of Nicotine Dependence; RCT, randomised controlled trial; NRT, nicotine 
replacement therapy; MDILog, metered-dose inhaler chronolog; IVR, interactive voice re-
sponse; CO, carbon monoxide; ppm, parts per million; PP, point prevalence; pts, patients; 
OR, odds ratio 
 
Appendix S1: Systematic review protocol 
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ID 
Country, Year 
and Study 
Population 
Participant 
characteristics 
Design & data 
collection 
Recall period 
/ length of 
follow-up 
Methods of 
recruitment 
Definitions Sample size Analysis method 
(incl. control of 
confounders) 
Main findings regarding 
the association between 
adherence and abstinence 
adherence success Baseline Follow-up 
[1] 
USA 
before 1999 
smokers (≥20/d) 
participating in a 
university-based 
cessation clinic 
38.7 ± 10.2 yrs 
53.5% women 
62.4% Caucas. 
26.4 ± 10.3 cig/d 
FTND 6.7 ± 1.5 
8-week patch Tx plus 
three levels of support 
(random.) 
questionnaires on 
withdrawal, motivation 
(URICA), self-efficacy 
week 9 and week 
26 
 
timeline follow-
back (TLFB) 
method 
University 
campus 
notices,  
newspaper ads, 
‘word of mouth 
continuously wearing 
the assigned 
patch at the recom-
mended patch dose 
in the 
instructed manner 
for the entire 24-h 
time period 
 
dichotomised 
measure of adher-
ence = patch use for 
more than the 
median number of 
days 
self-report (TLFB) of 
abstinence of 
unspecified duration, 
validated by CO<10 
ppm 
101 (34/34/33 in 
the 3 groups) 
“11 to 12 treat-
ment drop-outs”, 
a majority of 
whom were 
smoking at the 9- 
and 26-week 
follow-up! 
correlation analysis and 
logistic regression for 
predictors of abstinence 
no specific control for 
non-adherence due to 
relapse 
Week 9: correlation patch use / 
smoking: r=-0.50; p<0.0005; 
dichotomised adherence / absti-
nence: unadjusted OR 23.44 (6.51-
84.39); adjusted OR 3.22 (0.94-
11.07) 
Week 26: correlation patch use / 
smoking: r=-0.34; p=0.002; dichot-
omised adherence / abstinence: 
unadjusted OR 4.25 (1.28-14.12); 
adjusted OR 1.43 (0.33-6.18) 
[2] 
Australia, Canada, 
United Kingdom, USA 
2006-2008 
smokers or recent 
quitters who had used 
medication in the 
previous year 
45.5 ± 13.0 yrs 
60.5% women 
17.5 ± 9.2 cig/d 
NRT use: 80.5% (of 
these: OTC 68.3%) 
BUP/VAR use: 
19.5% 
ITC Four-Country 
Survey (CAN, UK, USA, 
and AUS),  
computer-assisted 
telephone interviews  
Waves 5 & 6 (10/06-
2/08), including only 
follow-ups that had 
been recruited at least 
one wave before 
12 months 
preceding the 
interview (retro-
spective) 
recruitm nt of 
smokers using 
random-digit 
dialling 
≥8 weeks of treat-
ment with NRT, BUP 
or VAR (sub-groups: 
<1 wk, 1-2 wks, 2-4 
wks, 4-8 wks, ≥8 wks) 
NRT: adequate dose: 
≥ 10 pcs/d 
self-reported 6-
month continuous 
abstinence; no 
biochemical valida-
tion 
1219 (920 
relapsers, 299 
successful 
quitters) 
use duration data 
available for 1118 
subjects; 
smoking outcome 
data available for 
548 subjects; of 
these, 22.6% 
achieved 6-mo 
cont. abstin., but 
201 were exclud-
ed (discontin. due 
to relapse) 
multiple logistic 
regression for predic-
tors of abstinence; all 
subjects who recalled 
having discontinued due 
to relapse were 
excluded (risk of recall 
bias) 
adjusted ORs for continuous 
abstinence at 6 mo (data for n = 
347): 
- non-adherence: 0.16 (0.08-0.31) 
- ‘not needed’ vs other reasons: 
3.26 (1.75-6.07) 
[3] 
USA 
2006-2007 
smokers ≥10/d 
47.3 ± 10.9 yrs 
66.8% women 
89.6% white 
19.7 ± 8.2 cig/d 
FTND 5.0 ± 2.1 
secondary analysis of 
the COMPASS Trial 
(VAR): 
smokers who set a quit 
date were mailed one 
28-day supply of VAR; 
three levels of support 
(random.) 
telephone 
interviews at 
baseline, 21 days, 
12 weeks, and 6 
months post 
target quit date 
brochures 
placed in health 
plan–owned 
clinics, physi-
cian referrals, 
Quit For Life 
Program 
4 self-report indices: 
a) days taken 
(dichotomised: ≥80% 
of prescribed 
amount) 
b) taken for 7 days 
before TQD 
c) taken for 7 days 
after TQD 
d) Medication 
Adherence Ques-
tionnaire (intentional 
vs. unintentional 
non-adherence) 
self-reported 7-day 
PP; no biochemical 
validation 
1161 
893 to 1161 
(depending on the 
adherence index 
examined); 
strange: the 
mother paper 
reports a 6-month 
sample size of 892 
logistic regression for 
predictors of 6-month 
continuous abstinence 
(using the 4 adherences 
indices) 
χ
2
 Test for assoc. btw. 
dichotomised adher-
ence and 7-day PP at 6 
months 
no specific control for 
non-adherence due to 
relapse 
unadjusted ORs for 7-day PP at 6 
months per 1 SD increase in the 
independent variable: 
a) 1.81 (1.56-2.09) 
b) 1.15 (1.00-1.33) 
c) 1.24 (1.07-1.44) 
d) less intentional non-adherence: 
1.23 (1.07-1.41) 
 
prevalence of 7-day PP at 6 months: 
52.2% (adherent) vs. 25.4% (non-
adherent); p<0.0001  
[4] 
USA 
2003-2005 
smokers ≥10/d 
42.7 ± 11.5 yrs 
51.8% women 
81.9% white 
22.6 ± 9.3 cid/d 
FTND 5.4  ±  2.1 
secondary analysis of 
an RCT of message 
framing for smoking 
cessation in addition to 
BUP 
timeline follow-
back (TLFB) 
method 
 
maximum follow-
up 26 weeks 
newspaper and 
radio ads, 
press releases, 
mailings to 
physicians, 
Internet 
Percentage adher-
ence = number of 
cap openings / 95 * 
100 
 
“Treatment comple-
tion” is mentioned 
but not defined 
self-reported 7-d PP 
at 6, 12 and 26 
weeks, validated by 
CO ≤10 ppm 
249 249 
linear and logistic 
regression, adjusted for 
message framing (i.e., 
rando group) 
no specific control for 
non-adherence due to 
relapse 
ORs of quitting at various time-
points, by mean percentage of cap 
openings: 
- 6-wk cont. abst.: 0.96 (0.95-0.98) 
- 7-d PP at 6 wks: 0.96 (0.95-0.97) 
- 7-d PP at 12 wks: 0.97 (0.96-0.99) 
- 7-d PP at 26 wks: 0.97 (0.95-0.99) 
[5] 
USA 
2003-2005 
smokers ≥10/d 
42.9 ± 11.6 yrs 
44.0% women 
81.6% white 
21.6 ± 9.1 cid/d 
FTND 5.3  ±  2.1 
secondary analysis of 2 
RCTs of VAR/BUP/PLC 
for smoking cessation 
12 weeks 
media advertis-
ing 
“completer”: 
subjects who took ≥1 
dose of medication 
for ≥80% of the 
treatment days 
self-reported 
abstinence wks 9-12, 
validated by CO ≤10 
ppm 
2045 (692 VAR, 
669 BUP, 684 PLC) 
2045 
logistic regression for 
predictors of abstinence 
no specific control for 
non-adherence due to 
relapse 
positive correlation between 
adherence to treatment and 
tobacco abstinence with no 
significant treatment-by-adherence 
interaction (data presented in a 
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during the 12-week 
treatment period 
figure; no ORs reported) 
[6] 
 
China 
2000-2002 
smokers attending a 
Smoking Cessation 
Health Centre  
85% aged 20-59 
20% women 
72% smoked >10/d 
43% with FTND≥5 
Prospective observa-
tional study 8/00-1/02; 
the cessation service 
(including a 1-wk 
supply of NRT) was 
free 
follow-up 
interviews 
including self-
administered 
questionnaires at 
1, 3 and 12 
months 
NRT use was 
asked about at 3 
months retrospec-
tively 
subjects 
reporting to the 
centre via 
phone or in 
person were 
invited to 
participate 
NRT use for ≥4wks 
during the first 3 
months (self-report 
at 3 months) 
self-reported 7-d PP 
at 12 months; no 
biochemical valida-
tion 
1186 of which 
89% received a 
prescription for 
NRT →1051 
3 months: 889 
12 months: 698 
logistic regression for 
predictors of abstinence  
no specific control for 
non-adherence due to 
relapse 
ORs for 7-d PP at 12 mo: 
- adherence to NRT: 1.97 (1.35-
2.88) 
- higher personal income: 1.82 
(1.38-2.41) 
- perceived health status as good: 
1.48 (1.09-2.02) 
- confidence in the ability to quit: 
1.53 (1.16-2.02) 
[7] 
USA 
1992 
elderly smokers (65-
74 yrs) 
69.3 ± 2.7 yrs 
75.2% women 
92.2% white 
no data on 
baseline smoking 
due to an error 
telephone survey; 
inclusion during the 
first quarter of 1992 
telephone 
interview 6 
months after NRT 
use (retrospec-
tive) 
Patients filing 
new claims for 
nicotine 
patches 
through the 
PACE program 
were invited 
no a priori definition 
of adherence 
self-reported PP at 6 
months; no biochem-
ical validation 
1070 of which 940 
turned out to be 
eligible 
871 pts. complet-
ed the interview 
T test to compare 
quitters and non-
quitters regarding the 
duration of NRT patch 
use 
no specific control for 
non-adherence due to 
relapse 
duration of patch use in quitters vs. 
non-quitters: 48.4 ± 31.9 days vs. 
32.0 ± 33.1 days (p<0.001) 
[8] 
United Kingdom 
2007-2008 
adults who had 
received prescriptions 
for varenicline 
mean age 46.5 yrs 
60.6% women 
THIN database: mailed 
questionnaire survey 
approximately 6 
months, retro-
spective 
data extraction 
(random 
sample) from 
an existing 
database 
no a priori definition 
of adherence 
self-reported 7-d PP 
at approximately 6 
months; no biochem-
ical validation 
915 193 
univariate logistic 
regression for predic-
tors of 6-month 
abstinence; no specific 
control for non-
adherence due to 
relapse 
ORs of abstinence for various 
treatment durations (ref: <2 
weeks): 
- 2-4 wks: 2.0 (0.6-6.1) 
- 5-8 wks: 5.4 (1.9-15.9) 
- 9-12 wks: 11.0 (3.9-31.1) 
- >12 wks: 7.6 (2.0-28.8) 
[9] 
Country: USA 
Year of study: not 
reported 
Population: smokers 
mean age: 42.8 ± 
11.5 yrs 
52.6% women 
87.3% white 
mean cig/d: 25.2 ± 
11.3 
secondary analysis of 
an RCT of nicotine 
patches vs. placebo 
under simulated over-
the-counter conditions 
6 weeks not reported 
adherence during 
wks 1-3 was cap-
tured in a patient 
diary 
definition of adher-
ence:  
a) patch use for ≥20 
of 21 treatment days 
(post-hoc definition) 
b) linear measure 
self-reported 7-d PP 
at 6 weeks, validated 
by CO<10 ppm 
567 371 
logistic regression for 
predictors of abstinence 
at 6 weeks 
control for relapse: The 
model controlled for 
smoking status during 
weeks 1-3 
OR of abstinence in adherent vs. 
non-adherent subjects (active group 
only): 3.25 (1.30-8.09); 53.2% vs. 
21.5% 
significant treatment-by-adherence 
interaction 
similar results when a linear 
measure of adherence was used 
[10] 
USA 
1992 
patients who received 
a nicotine patch 
prescription 
mean age ∼40 yrs 
57% women 
Telephone interviews 
between 9/92 and 
11/92 
between 3 and 10 
months (not 
specified), 
retrospective 
data extraction 
from an 
existing 
database 
no a priori definition 
of adherence 
self-reported PP at 
the time of the 
interview; no 
biochemical valida-
tion 
eligible: 404 
completed the 
interview: 284; 
subsample used: 
260  
within-group compari-
son (non-smokers) using 
T and χ
2
 tests; 
no specific control for 
non-adherence due to 
relapse 
Nonsmokers were more likely to 
have used the patch longer than 
shorter (5-level variable) and to 
report having used the patch every 
day as compared to less frequently 
(3-level variable) 
[11] 
Sweden 
before 1984 
no further infor-
mation 
mean age: 40.7 yrs 
56% women 
mean cig/d: 19.0 
mean FTND: 6.3 
RCT of long vs. short 
support and gum vs. 
no gum (2x2 design) 
mailed question-
naire or phone call 
at 6 & 12 months 
enrolment 
through 
participating 
physicians 
“arbitrary criterion”: 
chewing ≥10 pieces 
per day 
self-reported PP at 6 
and 12 months, 
validated by CO≤4 
ppm at 6 mo in a 
subsample (n = 26) 
151 145 
descriptive analysis 
no specific control for 
non-adherence due to 
relapse 
PP at 12 mo for adherent vs. non-
adherent pts: 30% vs. 22% 
[12] 
USA 
before 1989 
smokers ≥1 pack/day 
mean age ∼42 yrs 
∼53% women 
∼27 cig/d 
mean FTND ∼6.5 
RCT of behavioural Tx 
vs. ‘education’ and 
fixed vs. ad lib gum 
(2x2 design); the 
treatment phase lasted 
11 weeks 
6 months newspaper ads 
compliance index: 
pieces chewed / 
pieces scheduled 
An index of >0.6 was 
considered ‘suffi-
cient’  
self-reported 48-h 
PP, validated by 
CO<8 ppm at 10 wks 
and by saliva cotinine 
<10 ng/ml at 6 
months 
107 
89 of which 82 
provided data at 6 
months 
descriptive analysis 
no specific control for 
non-adherence due to 
relapse 
“Average gum use did not correlate 
significantly with any outcome 
variable” (no data provided, except 
for a subgroup analysis for n = 10 
with no p values in Table 2) 
[13] 
Italy 
2007-2008 
smokers motivated to 
quit 
51.1 ± 10.7 yrs 
56.3% women 
22.8 ± 8.8 cig/d 
mean FTND ∼5.5 
non-randomised trial 
of VAR vs. PLC (self-
selection) in addition 
to a 6-wk group 
cessation course 
12, 26 and 52 
weeks 
outpatient 
clinic 
taking VAR for 12 
weeks 
self-reported PP, 
validated by CO<10 
ppm in 22 subjects at 
12 months 
112 
110 of which 48 
self-selected to 
take VAR and 
were included in 
the analysis 
propensity score 
matching (to account 
for self-selection) 
χ
2
 test 
no specific control for 
non-adherence due to 
PP at 12 months: 62.5% (adherent) 
vs. 53.1% (non-adherent); p=0.381 
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relapse 
[14] 
USA 
2003-2006 
heavy drinking 
smokers ≥10/d 
41.5 ± 12.0 yrs 
45% women 
90.7% white 
21.3 ± 9.4 cig/d 
FTND 5.0 ± 2.2 
RCT of adding a brief 
alcohol intervention to 
a 4-week individual 
smoking cessation 
treatment; all pts. 
received NRT patches 
maximum follow-
up 26 weeks 
community 
bulletin boards, 
newspaper & 
radio ads 
Percent days of using 
patch during was 
used as the index of 
compliance with 
nicotine patch 
self-reported 7-d PP, 
validated by CO≤10 
ppm and saliva 
cotinine ≤15 ng/ml at 
16 & 26 weeks 
236 
2 wks: 222 
8 wks: 220 
16 wks: 213 
26 wks: 222 
GEE models predicting 
7-d PP 
no specific control for 
non-adherence due to 
relapse 
OR of quitting for greater adher-
ence: 2.23; p <0.0001 (no 95% CI 
provided) 
[15] 
USA 
2001-2004 
smokers ≥10/d 
46.1% women 
86% white 
RCT of extended BUP 
vs. PLC following an 
11-wk programme 
with BUP + NRT 
Last clinic visit at 
week 25; tele-
phone follow-up 
(IVR system) until 
52 months 
Internet, 
newspaper 
&radio ads, 
local organiza-
tions (12/01-
3/04) 
positive answer to 
the questions “Are 
you wearing a patch 
now” and “Have you 
taken your pill this 
morning?”  
no clear definition of 
adherence 
self-reported PP, 
validated by CO<10 
ppm at 52 weeks 
(special appointment 
for self-reported 
non-smokers) 
362 362 
logistic regression 
no specific control for 
non-adherence due to 
relapse 
OR of quitting for more frequent 
use of study medication (including 
placebo) at... 
- 25 wks: 1.7 (1.5-2.0) 
- 52 wks: 1.61 (1.4-1.9) 
[16] 
USA 
before 2007 
female smokers ≥10/d 
47.8 ± 9.3 yrs 
100% women 
70.1% white 
21.4 ± 9.2 cig/d 
FTND 5.8 ± 2.3 
RCT of BUP vs. PLC and 
CBT vs. support (2x2 
design) 
12 months, but 
the association 
between adher-
ence and absti-
nence was only 
assessed at 7 
weeks (EOT) 
radio, televi-
sion and print 
ads 
MEMS: adherence = 
taking 2 doses/d  
Adherence score = 
days of adherence / 
42 days of Tx 
self-reported 7-d PP, 
validated by CO and 
salivary cotinine <15 
ng/ml 
154 
EOT: 81 
3 mo: 69 
6 mo: 60 
9 mo: 69 
12 mo: 70 
logistic regression for 
predictors of abstinence 
at 7 weeks 
no specific control for 
non-adherence due to 
relapse 
For participants receiving BUP, 
adherence 
levels did not predict abstinence 
rates at EOT  
[17] 
USA 
2001-2003 
smokers treated at a 
tobacco dependence 
clinic 
44 ± ?? yrs 
61% women 
71% Caucas. 
22 ± ?? cig/d 
retrospective cohort 
analysis of smokers 
using ≥1 form of NRT 
4-wk data were 
collected at visits 
or by phone 
26-wk data were 
collected by 
phone or mail 
not described 
no a priori definition 
of adherence 
self-reported 7-d PP 
at 4 and 26 weeks, 
validated by CO<10 
ppm in a subsample 
(n=255) at 4 weeks 
790 
26 wks: 626 
(dropouts were 
considered to be 
smoking and not 
using NRT) 
χ
2
 test 
no specific control for 
non-adherence due to 
relapse after 4 weeks 
7-d PP at 6 months in those using 
NRT for ≥6 mo vs. <6mo: 65% vs. 
27%; p<0.001 (subgroup of those 
who were abstinent at 4 wks: 82% 
vs. 52%; p<0.01) 
[18] 
United Kingdom 
before 1987 
smokers working in a 
retailing company 
34.3 ± 10.6 yrs 
70% women 
15.5 ± 7.6 cig/d 
quasi-randomised trial 
of a 2-session cessa-
tion programme (of 
334 interested 
smokers, only 270 
were invited, and 172 
of these took part) 
NRT had to be 
purchased 
12 months 
mailing of 
invitation 
letters to 
employees 
use of >1 box of 
nicotine gum (105 
pieces) 
self-reported 
continuous 12-month 
abstinence (lenient 
or strict definition), 
validated by CO<10 
ppm 
334 
12 mo: 331 were 
interviewed, but 
only 303 in person 
descriptive analysis 
no specific control for 
non-adherence due to 
relapse 
12-month continuous abstinence 
rates in those using >105 pieces of 
gum vs. those using ≤ 105 pieces: 
19% vs. 9% (no p value given) 
[19] 
United Kingdom 
before 1988 
smokers working in 
four companies 
40 ± ?? yrs 
43% women 
19 ± ?? yrs 
quasi-randomised trial 
of a 3-month cessation 
programme 
NRT had to be 
purchased 
12 months 
participants of 
an earlier trial 
of videos to 
support 
quitting 
use of >1 box of 
nicotine gum (105 
pieces) 
self-reported PP at 
12 months, validated 
by CO<10 ppm 
161 (79 interv., 82 
control) of which 
32 entered the 
programme 
161 
descriptive analysis 
no specific control for 
non-adherence due to 
relapse 
no significant association between 
amount of gum used and absti-
nence 
[20] 
USA 
before 2000 
smokers ≥10/d 
mean age ∼46 yrs 
∼46% women 
∼87% white 
∼25.5 cig/d 
 
RCT of 2 different 
doses of paroxetine or 
PLC in addition to 
nicotine patches 
4, 10 and 26 
weeks (interactive 
voice response 
system) and clinic 
visits in those who 
claimed to be 
abstinent) 
newspaper ad 
no a priori definition 
of adherence 
self-reported 7-d PP 
at 10 & 26 wks, 
validated by CO <9 
ppm and saliva 
cotinine <20 ng/ml 
224 224 
logistic regression for 
the association between 
the number of affirma-
tive statements on 
adherence on the 
telephone and absti-
nence at 4 weeks 
OR of abstinence at 4 weeks for 
more affirmative statements: 3.27 
(2.0-5.2) 
[21] 
USA 
before 1992 
smokers (50% were 
employees of the 
hospital where the 
study was conducted) 
38.9 ± 8.9 yrs 
66.6% women 
28.4 ± 12.5 cig/d 
FTND 6.6 ± 1.7 
observational study of 
voluntary NRT use in a 
10-session group 
cessation programme 
6 months 
hospital 
publications 
subjects completed a 
questionnaire on 
gum use 3 wks after 
TQD 
adherence = used as 
recommended 
self-reported PP at 6 
mo, validated by CO 
(no cut-off provided) 
36 36 
T tests, χ
2
 tests 
no specific control for 
non-adherence due to 
relapse 
abstinence rates in adherent vs. 
non-adherent subjects: 50% vs. 83% 
(n.s.) 
[22] 
USA 
2003-2004 
African-American light 
smokers (≤10/d) 
45.1 ± 10.7 yrs 
66.9% women 
7.6 ± 3.2 cig/d 
secondary analysis of 
an RCT (name: ‘KIS’; 
full name not provid-
ed) of health educ. vs. 
MI and nicotine gum 
weeks 1, 3, 6, 8, 
and 26 
not reported 
use of ≥75% of the 
prescribed dose 
self-reported 7-d PP 
at 26 wks, validated 
by saliva cotinine≤20 
ng/ml 
755 of which 378 
were randomised 
to verum (gum) 
week 26: 637 
662 were included 
in the adherence 
analyses 
descriptive analyses and 
multiple logistic 
regression for predic-
tors of abstinence 
no specific control for 
abstinence rates at 26 wks for 
adherent vs. non-adherent subjects: 
9.5% vs. 16.7% (no p value given) 
 
adjusted OR of quitting for adher-
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vs. PLC (2x2 design); 
3/03-6/04 
non-adherence due to 
relapse 
ence to study medication (including 
placebo) at 26 wks: 0.50 (0.28-0.87) 
[23] 
USA 
before 1995 
smokers 
42.2 ± 9.7 yrs 
51% women 
33.0 ± 10.6 cig/d 
FTND 7.8 ± 1.5 
RCT of 4 gum use 
durations (0 / 7 / 15 / 
30 pcs/d) in addition to 
minimal support 
up to 24 weeks 
newspaper and 
radio ads 
no a priori definition 
of adherence; gum 
use was assessed by 
self-report 
CO≤10 ppm 177 177 
ANOVA (4 groups) 
no specific control for 
non-adherence due to 
relapse 
no overall effect of gum-group 
assignment on abstinence 
[24] 
United Kingdom 
1980 
smokers who were 
offered NRT gum 
mean age: 40 yrs 
56% women 
mean cig/d: 17.9 
subgroup analysis of a 
cessation intervention 
trial 
4 and 12 months not reported 
Categorical variable 
‘gum use’: 0 / 1-14 
pcs / 15-105 pcs / 
>105 pcs 
self-reported PP at 4 
& 12 mo, validated 
by CO in a subsample 
at 12 months 
679 474 
logistic regression for 
predictors of abstinence  
no specific control for 
non-adherence due to 
relapse 
Use of >105 pcs/d was associated 
with significantly higher 4-mo and 
12-mo abstinence rates that use of 
≤105 pcs/d. 
ORs are not reported 
[25] 
USA 
1989-1990 
highly-dependent 
smokers (FTND≥7) 
mean age ∼40 yrs 
42.8% women 
97% Caucas. 
mean FTND ∼8.4 
RCT of 2 doses of 
nicotine gum (4 / 2 mg) 
vs. PLC in addition to a 
minimal intervention; 
5/89-5/90 
6 weeks not reported 
using an average of 
≥9 pcs/d 
continuous 28-day 
abstinence at week 
6, validated by 
CO<10 ppm 
563 216 
4-wk abstinence was 
calculated separately 
for adherent and non-
adherent pts. in the 
three groups but were 
only compared between 
groups 
abstinence rates in adherent 
subjects: 56% (4 mg) / 33% (2 mg) / 
33% (PLC); p = 0.0016 (no sign. 
difference in non-adherent 
subjects) 
[26] 
USA 
before 1999 
heavy smokers 
(>25/d) 
mean age ∼47 yrs 
41.4% women 
∼82.5% white 
mean cig/d ∼36 
RCT of 25 mg vs. 15 mg 
nicotine patches (6 
weeks) in addition to 
self-help material 
2 mo (clinic visit) 
6 & 12 months 
(phone visit) 
newspaper ads 
adherence was 
assessed at 1, 2, 4 & 
6 wks (IVR system) 
definition of adher-
ence: positive 
answer to the 
question “Are you 
wearing a patch 
now?” 
self-reported 7-d PP 
at various time-
points, validated by 
CO<9 ppm and saliva 
cotinine <20 ng/ml at 
2 months 
408 
IVR calls: 
wk 1: ∼380 
wk 2: ∼370 
wk 4: ∼350 
wk 6: ∼290 
χ
2
 Test comparing 
adherent and non-
adherent subjects 
no specific control for 
non-adherence due to 
relapse 
validated abstinence rates at 2 
months in adherent vs. non-
adherent subjects: 28% vs. 11% 
(p<0.001) 
[27] 
USA 
before 2007 
female smokers ≥10/d 
42.1 ± 10.0 yrs 
100% women 
61.8% Caucas. 
20.8 ± 8.8 cig/d 
FTND 5.0 ± 2.5 
RCT of using MEMS 
feedback to increase 
adherence to a 7-wk 
course of BUP 
6 weeks not reported 
MEMS: a) dose 
adherence =taking 2 
doses per day; b) full 
adherence = 2 doses 
per day, 8-12 h apart 
The intervention 
group received an 
intervention to 
increase adherence! 
self-reported 7-d PP 
at 3 & 6 weeks, 
validated by CO (no 
specific information 
provided) 
55 (intervention 
27, control 28) 
24 overall 
effect sizes expressed in 
terms of multiple 
regression coefficients 
no specific control for 
non-adherence due to 
relapse 
At 3 & 6 wks, both types of adher-
ence were associated with higher 
abstinence rates (all p<0.05) 
[28] 
USA 
2009-2010 
black smokers >10/d 
46.8 ± 11.3 yrs 
62.5% women 
100% black 
16.3 ± 5.4 cig/d 
RCT of adherence 
support vs. usual care 
in addition to a 12-wk 
course of VAR; 3/09-
8/09 
12 weeks not reported 
adherence was 
assessed by pill 
counts and is 
expressed as a 
percentage 
self-reported 7-d PP 
at 12 wks, validated 
by saliva cotinine <20 
ng/ml 
72 
4 weeks: 60 
8 weeks: 57 
12 weeks: 61 
χ
2
 test 
no specific control for 
non-adherence due to 
relapse 
adherence in quitters vs. relapsers 
at 12 weeks: 95.8% vs. 80.8%; 
p<0.05 
[29] 
USA 
2004 
homeless smokers 
mean age ∼44 yrs 
∼39.1% women 
∼30% white 
mean cig/d ∼15 
mean FTND ∼4 
RCT of two different 
counselling formats in 
addition to NRT (self-
selection of patch or 
gum); 2/04-12/04 
26 weeks (associa-
tion between 
adherence & 
abstinence was 
only assessed at 8 
weeks) 
flyers distribut-
ed at 13 
homeless 
service facilities 
adherence to patch: 
1 patch/d 
adherence to gum: 
according to a 
tailored dosing 
schedule (no details 
provided) 
self-reported 7-d PP 
at 26 wks, validated 
by CO<10 ppm and 
saliva cotinine ≤20 
ng/ml 
46 28 
χ
2
 test (presumably) 
no specific control for 
non-adherence due to 
relapse 
abstinence rates at 8 wks for use of 
≥4 vs. <4 patches/wk: 33.3% vs. 
10.5%; p=0.3 (This information is 
only given in the abstract, not in the 
paper) 
[30] 
USA 
1989 
highly-dependent 
smokers (FTND≥7) 
mean age ∼43 yrs 
44% women 
∼91% white 
RCT of 3 doses of 
nicotine gum (4 / 2 / 
0.5 mg) 
1, 2, 4 and 6 
weeks after TQD 
newspaper ads 
pts. were instructed 
to use 12 pcs/d and 
to complete a usage 
diary 
continuous 28-day 
abstinence at week 
6, validated by CO<8 
ppm 
90 90 
Mann-Whitney test 
no specific control for 
non-adherence due to 
relapse 
At 6 weeks, abstinent subjects had 
used significantly more gum than 
relapsers (10.9 ± 2.1 vs. 9.7 ± 1.6 
pcs/d; p < 0.03); this effect was 
driven by a significant finding in the 
4 mg group 
[31] 
Denmark 
before 1993 
smokers ≥10/d 
mean age ∼39 yrs 
∼60% women 
mean cig/d ∼20 
mean FTND ∼7.3 
RCT of nicotine inhaler 
vs. PLC 
12 months 
(association 
between adher-
ence & abstinence 
was only assessed 
at 6 weeks) 
newspaper ads 
pts. were instructed 
to use 2-10 inhal-
ers/d and to com-
plete a usage diary 
for the first 3 wks of 
the trial 
self-reported 
continuous absti-
nence at 12 months, 
validated by CO<10 
ppm 
286 12 months: 273 
logistic regression for 
predictors of abstinence 
at 6 weeks 
no specific control for 
non-adherence due to 
relapse 
In the active group, abstinent 
subjects at week 6 had used more 
inhalers/d than relapsers (p=0.008) 
OR of abstinence at 6 weeks for 
number of inhalers used: 1.41 (no 
CI provided) 
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[32] 
Malaysia 
2009-2010 
smokers working at 
two public universities 
35.9 ± 10.9 yrs 
0% women 
observational study of 
a behavioural interven-
tion and free NRT; 
11/09-6/10 
8 weeks 
invitation letter 
and e-mail, 
Health screen-
ings, ‘Wellness 
Day’ 
NRT use for ≥2 weeks 
validated by CO<10 
ppm 
185 not reported 
logistic regression for 
predictors of abstinence 
at 2 months 
no specific control for 
non-adherence due to 
relapse 
According to the abstract, adher-
ence to NRT was a univariate 
predictor of cessation (p<0.001). 
Apparently, adherence was not 
entered in the multivariate model. 
[33] 
USA 
2005-2008 
smokers ≥10 cig/d 
with attention-deficit/ 
hyperactivity disorder 
37.8 ± 10.0 yrs 
43.5% women 
82.6% white 
19.9 ± 7.7 cig/d 
FTND 5.5 ± 2.2 
secondary analysis of 
an RCT of 
methylphenidate or 
PLC in addition to 
nicotine patches and 
counselling; 12/05-
1/08 
10 weeks 
advertising, 
letters to clinic 
patients,  
networking 
with communi-
ty professionals 
self-reported patch 
adherence: number 
of patches used 
divided by the 
number dispensed 
a) prolonged 
abstinence during 
weeks 7-10 (i.e. not 
smoking on 7 
consecutive days or 
at least once per 
week for 2 consecu-
tive weeks) 
b) self-reported 
continuous absti-
nence weeks 7 
through 10, validated 
by CO (no cut-off 
provided) 
c) self-reported 7-d 
PP at 10 weeks 
255 not reported 
mediation model to 
assess relationships 
between thoughts 
about abstinence 
(predictors), adherence 
(mediator) and absti-
nence (outcome); 
bootstrapped logistic 
regression 
no specific control for 
non-adherence due to 
relapse 
When factoring out predictor 
variables, the mediator variable 
‘patch adherence’ was positively 
associated with all three outcomes 
(regression coefficients around 0.3). 
[34] 
Korea 
2007-2009 
smokers attending a 
smoking cessation 
clinic 
mean age ∼48 yrs 
0% women 
median cig/d: 20 
median FTND: 5 
retrospective analysis 
of smokers receiving 
VAR as part of a 
cessation programme 
(9/07-12/09) 
6 months not reported 
no a priori definition 
of adherence; no 
description of 
adherence meas-
urement (presuma-
bly self-report) 
self-reported 6-
month continuous 
rate, validated by CO 
(no cut-off provided) 
87 78 
logistic regression for 
predictors of 6-month 
continuous abstinence 
no specific control for 
non-adherence due to 
relapse 
unadjusted OR of abstinence per 
additional week of medication use: 
1.123 (1.032-1.222) 
adjusted OR: 1.172 (1.052-1.305) 
[35] 
USA 
before 2004 
smokers ≥10 cig/d 
43.3% women 
RCT of three intensities 
of cognitive-
behavioural support in 
addition to free 
nicotine patches 
7 weeks,  
6 months, 
12 months 
subjects were 
directly 
approached by 
primary care 
providers 
three levels of 
adherence (self-
report at 7 weeks): 
- full: using all 
patches 
- partial: using most 
or some patches 
- none: using a bit or 
none of the patches 
self-reported 7-d PP 
at 7 wks, 6 months 
and 12 months, 
validated by CO <10 
ppm 
619 
7 weeks: 485 
6 months: not 
reported 
12 months: not 
reported 
logistic regression for 
predictors of abstinence  
no specific control for 
non-adherence due to 
relapse  
OR of abstinence in fully adherent 
(vs. all other groups) subjects: 
- 7 weeks: 1.71 (1.14–2.58) 
- 6 months: 2.47 (1.56–3.91) 
- 12 months: 2.12 (1.34–3.37) 
[36] 
USA 
before 1997 
smokers 
mean age ∼44 yrs 
49.5% women 
∼82% white 
mean cig/d ∼23 
secondary analysis of 
an RCT (2 x 2 factorial 
design) of nicotine 
patch (21 mg) vs. PLC 
and self-help with vs. 
without video 
2, 6 and 12 
months 
newspaper ads 
current patch use 
was assessed via 
telephone at 24 hrs, 
1 week, 1 month and 
2 months. Full 
compliance was 
defined as answering 
‘yes’ at all assess-
ments 
self-reported 7-d PP 
at 2, 6 and 12 
months, validated by 
CO <9 ppm and saliva 
cotinine <20 ng/ml 
424 
6 months: 410 
12 months: 410 
Cox proportional hazard 
analysis of time to 
relapse with compliance 
status entered as an 
independent variabe 
Patch compliance status entered 
the model at 2 months (p<0.001), 6 
months (p<0.001) and 12 months 
(p<0.001). 
[37] 
United Kingdom 
2001-2003 
smokers attending 
Stop Smoking Services 
44 ± 12.7 yrs 
57% women 
91% white 
22.2 ± 9.5 cig/d 
FTND 5.8 ± 2.1 
prospective observa-
tional study including 
smokers setting a quit 
date and using BUP; 
1/01-12/03 
4 weeks not reported 
no a priori definition 
of adherence; BUP 
use was assessed by 
self-report 
self-reported 14-d PP 
four weeks after the 
quit date, validated 
by CO <10 ppm 
388 388 
χ
2
 test 
no specific control for 
non-adherence due to 
relapse 
14-d PP at four weeks depending on 
BUP use in the week prior to the 
quit date: 44% (≥14 tablets) vs. 32% 
(<14 tablets); p = 0.26 
 
Table S1: Characteristics of studies which were excluded due to a lack of control for confounding by non-adherence due to relapse 
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Appendix 
SYSTEMATIC REVIEW PROTOCOL 
A systematic review of studies assessing the association between  
adherence to smoking cessation medication and treatment success 
 
A number of studies suggest an association between the dose of cessation medication 
(i.e., daily dose or duration of use) and abstinence from smoking. There are two 
possible explanations for this finding: (1) Adherence to dosing regimens could be 
causally related to higher abstinence rates (i.e., non-adherence is a risk factor for 
failing to quit). (2) Patients who relapse may stop taking their medication. Thus, 
relapse during the study period could precipitate non-adherence in which case a 
reverse causality must be assumed (i.e., relapse precipitates non-adherence). Studies 
aimed at demonstrating that continuous abstinence is causally linked to medication 
adherence need to control for confounding by reverse causality. This can be done by 
either excluding all participants who relapsed before stopping their medication or by 
assessing adherence during a pre-specified treatment period and determine abstinence 
only in those subjects who had been continuously abstine t throughout this period.  
 
Review Questions 
Is there an association between adherence to cessation medication and continuous 
abstinence from smoking if reverse causality is being controlled for? 
 
 
Search terms 
Smoking cessation AND (adherence OR compliance) AND (abstinence OR success); 
(nicotine replacement OR bupropion OR varenicline) AND (adherence OR 
compliance) 
The search terms are deliberately inclusive so that papers are not missed.  
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Databases searched 
Pubmed, WebOfScience, the Cochrane Tobacco Addiction Group specialized register 
 
Hand search 
Reference lists of included studies 
 
Researchers contacted for knowledge of unpublished data/ongoing studies 
- Professor Jonathan Foulds 
 
Study Selection Criteria 
Inclusion criteria 
- General population sample (i.e. not recruited for particular clinical conditions)  
- Adult participants (≥18 years of age) 
- First-line treatments (nicotine replacement therapy, bupropion, varenicline) alone 
or in combination 
- Prospective design 
- Specifically examining the association between medication adherence and 
continuous abstinence from smoking 
- Published in peer-reviewed journals 
- Written in English 
- specific analysis controlling for reverse causality 
 
Exclusion criteria 
- Retrospective surveys (risk of confounding by recall bias) 
- Review articles 
- personal communications to editors 
- commentaries 
- study protocols 
- case studies 
- studies on smoking reduction 
- studies involving pregnant women and adolescents 
 
Search procedure 
The lead reviewer will select studies for inclusion in the review.  A second reviewer 
will independently screen all papers for suitability (using the study eligibility for 
review form). 
 
Data to be extracted 
- Study design 
- Study sample and selection 
- Outcome definition and measures 
- Recall period 
- Response rate 
- Analysis 
 
Data extraction strategy 
Details of the studies agreed to be eligible for the review will be extracted and 
compiled into tables by the lead researcher and double-checked.  All details in the 
table will be examined by a second reviewer highlighting any errors in extraction or 
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discrepancies in interpretation between the reviewers.  Any discrepancies will be 
discussed and resolved with the opinion of the other reviewers where necessary. 
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Study Eligibility for Review Form 
 
 
General Information 
 
 
Pubmed ID: 
 
 
Study Title: 
 
 
 
Author contact details: 
 
 
 
 
Identification number in the systematic review: 
 
 
 
Identification of reviewer:  
 
 
 
 
Study Characteristics 
Verification of study eligibility 
           
1)  General population sample         
2) Adult participants ( e.g. ≥ 18 years)         
3) First-line treatments (NRT, bupropion, varenicline)     
4) Prospective design         
5) Specifically examining the association between medication adherence and 
continuous abstinence from smoking            
6) Written in English         
 
 
 
Notes: 
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Table 1: Characteristics of studies examining the association between medication adherence and quitting success 
 
 
ID 
Country, Year 
and Study 
Population 
Participant 
characteristics 
Design & data 
collection 
Recall period 
/ length of 
follow-up 
Methods of 
recruitment 
Definitions Sample size Analysis method 
(incl. control of 
confounders) 
Main findings regarding 
the association between 
adherence and abstinence 
adherence success Baseline Follow-up 
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Tables of outcome 
Data will be extracted and entered into the table by the lead reviewer and also 
independently by a second reviewer. Any discrepancies will be recorded, discussed and 
resolved. 
 
Table 1: Studies examining the association between adherence and continuous 
abstinence and controlling for reverse causation.  
 
Table 2: Studies examining the association between adherence and continuous 
abstinence without cont olling for reverse causation. 
 
NOTES:  
• If more than one definition of success is examined (e.g. 1 week abstinence and 6 
months abstinence) the longest length of abstinence that was linked to adherence 
data will be included in the study (i.e. 6 months). 
• Where the association has been examined over multiple countries, the combined 
data-set will be used where available in preference to those that examine the 
association within each country individually. 
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 Systematic review – second reviewer guide 
 
1. Search through the 483 titles and abstracts and extract those that are eligible for 
the study. Please also note the reference of the studies that you required a full-
text document to ascertain if eligible. Please use the following codes to record 
the reasons for exclusion: 
 
1 not written in English 
2 no original data – review  article 
3 no original data – personal communications, commentaries, case reports, 
study protocols, replies to other articles or “patient pages” 
4 unrelated to smoking cessation (but other conditions or smoking reduction) 
5 unrelated to pharmacotherapy 
6 unrelated to adherence 
7 including adolescents or pregnant women 
8 other (e.g., no specific research question related to the association between 
adherence and quitting success / predictors of adherence) 
10 no control for reverse causation 
 
 
2. Check that you agree with all details entered in the Table (i.e. summary of 
included studies).  Alter using track changes 1) any incorrect details, 2) details 
not needed, and 3) add anything missed that might be relevant  
 
• Note any factors which you feel would be important to include in quality 
assessment of the studies.   
 
 
Thank you! 
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